As the IPO window remains shut, tech and life sciences companies and the law firms that serve them are going back to the boardroom.

Late-stage private companies are increasingly employing common cost-cutting measures and contemplating down-round financings, as well as alternatives to traditional equity financings, according to a new report from Wilson Sonsini Goodrich & Rosati.